Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Therapeutic Advances in Medical Oncology|March 21, 2022
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancerAditya Bardia, Javier Cortes, Sara A Hurvitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2013
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerSara A Hurvitz, Luc Dirix, Judit Kocsis, et al.
Breast Cancer Research and Treatment|July 14, 2017
Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancerJohn V Hegde, Xiaoyan Wang, Deanna J Attai, et al.
Clinical Breast Cancer|October 21, 2017
Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast CancerJohn V Hegde, Xiaoyan Wang, Deanna J Attai, et al.
JNCI Cancer Spectrum|July 28, 2022
Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer PatientsJulienne E Bower, Patricia A Ganz, Michael R Irwin, et al.
Breast Cancer Research and Treatment|February 10, 2015
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of responseSara A Hurvitz, Ondrej Kalous, Dylan Conklin, et al.
Annals of Surgical Oncology|September 14, 2016
Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary ClinicAmar U Kishan, Caitlin L Gomez, Nicole A Dawson, et al.
Future Oncology (London, England)|July 29, 2024
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancerErika P Hamilton, Cynthia Ma, Michelino De Laurentiis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2021
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)Aditya Bardia, Sara A Hurvitz, Angela DeMichele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2014
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKTNeil A O'Brien, Karen McDonald, Luo Tong, et al.
Pageof 14